We have previously reported that transcriptional induction of cyclooxygenase-2 (COX-2) isoenzyme occurs early after T cell receptor triggering, suggesting functional implications of cyclooxygenase activity in this process. Here, we identify the cis-acting elements responsible for the transcriptional activation of this gene in human T lymphocytes. COX-2 promoter activity was induced upon T cell activation both in primary resting T lymphocytes and in Jurkat cells. This induction was abrogated by inhibition of calcineurin phosphatase with the immunosuppressive drug cyclosporin A, whereas expression of an active calcineurin catalytic subunit enhanced COX-2 transcriptional activation. Moreover, cotransfection of nuclear factor of activated T cells (NFAT) wild type protein transactivated COX-2 promoter activity. Conversely, dominant negative mutants of NFATc or c-Jun proteins inhibited COX-2 induction. Electrophoretic mobility shift assays and site-directed mutagenesis allowed the identification of two regions of DNA located in the positions ؊117 and ؊58 relative to the transcriptional start site that serves as NFAT recognition sequences. These results emphasize the central role that the Ca 2؉ /calcineurin pathway plays in COX-2 transcriptional regulation in T lymphocytes pointing to NFAT/activator protein-1 transcription factors as essential for COX-2 promoter regulation in these cells.
Prostaglandin endoperoxide synthase or cyclooxygenase (COX) 1 is the enzyme responsible for the conversion of arachidonic acid to prostaglandin H 2 , the main step in the prostaglandin synthesis pathway. Two forms of the enzyme, named COX-1 and COX-2, have been shown to be expressed in mammalian tissues. COX-1 is considered a housekeeping enzyme constitutively expressed in most tissues, whereas the COX-2 isoform is induced by several stimuli including cytokines and mitogens and is thought to be responsible for the increased production of prostaglandins in pathologic processes (reviewed in Refs. [1] [2] [3] . Promoter regions of the COX-2 gene of mouse (4) , rat (5), chicken (6) , and humans (7-9) have been cloned. Regardless of the animal species, these promoters contain a classical TATA box, an E-box, and binding sites for transcription factors such as nuclear factor B, nuclear factor-IL6/CCAATenhancer binding protein), and cyclic AMP-response element (CRE) -binding proteins. These sequences have been shown to act as positive regulatory elements for the COX gene transcription in different cell types (5, 10 -14) . We have recently shown that COX-2 expression is induced in T cells upon T cell receptor (TCR) activation playing an important role in controlling this process (15) . However, no studies about COX-2 promoter regulation in these cells have been reported so far.
Activation of T cells triggers a complex regulatory cascade of events that culminates in the induced transcription of a variety of activation-associated genes (16 -18) . Many of them are cytokines that in turn regulate cell proliferation, differentiation, and acquisition of effector functions by cells of the immune system. The signal transduction pathways involved in T cell activation include those mediated by calcium and protein kinase C (PKC) that contribute to the induction and activation of several transcription factors including nuclear factor B, AP-1, NFAT and octamer binding factors, known to regulate cytokine gene expression (19) . The rise in intracellular calcium triggered by antigen binding to the TCR⅐CD3 complex leads to the activation of calcineurin phosphatase activity, which dephosphorylates cytoplasmic members of the NFAT family of transcription factors (20 -23) . Dephosphorylated NFAT proteins enter the nucleus and interact with Fos and Jun family members to cooperatively bind to and transactivate NFAT sites (24, 25) . This process of T cell activation and transcription of cytokine genes is blocked by inhibition of calcineurin phosphatase activity by the immunosuppressive drug cyclosporin A (CsA) (26 -28) .
Here we have analyzed the regulation of COX-2 gene expression in human T cells, showing that COX-2 promoter activity was induced upon T cell activation in a CsA-sensitive manner. Conversely, expression of a calcineurin constitutively active catalytic subunit increased promoter activity. Further analysis involved NFAT and AP-1 transcription factors in the regulation of COX-2 expression. Finally, we localized two NFAT binding sites in the Ϫ117 and Ϫ81 positions from the transcription start site required for induction of COX-2 promoter activity. These results indicate that Ca 2ϩ /calcineurin and PKC/AP-1 signaling transduction pathways are essential for induction of COX-2 gene expression in T cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents-The Jurkat human leukemic T cell line was cultured in RPMI medium supplemented with 10% fetal bovine serum and 2 mM glutamine and antibiotics. Purified human peripheral blood T lymphocytes (PBTs) were obtained as described previously (15) from partially purified human blood by the Ficoll-Hypaque gradient. The peripheral blood lymphocyte fraction was plated, and a not adherent population was passed through a nylon fiber wool column. Cells were collected and resuspended in RPMI plus 10% fetal bovine serum and 2 mM L-glutamine and antibiotics. The purity of the PBT population, detected by flow cytometry, was always greater than 95% CD3 ϩ cells. Cells were stimulated by phorbol 12-myristate 13-acetate (PMA; Sigma) at 15 ng/ml and/or A23187 calcium ionophore (Ion; Sigma) at 1 M. CsA (Sandoz) (100 ng/ml) was added 1 h before the addition of PMA and Ion.
Plasmid Constructs-Human COX-2 promoter constructs were generated by cloning BamHI-BglII-flanked PCR products derived from Jurkat genomic DNA into the BglII-digested pXP2LUC reporter plasmid (29) . An unique reverse primer starting from ϩ104 bp was used for PCR amplification (5Ј-gggagatctGGTAGGCTTTGCTGTCTGAGG-3Ј). Different forward primers lying in the 5Ј-region of the transcription start site of the promoter were used to obtain the deletion constructs: Ϫ1796, 5Ј-gggggatccGGATTCTAACATGGCTTCTAACCC-3Ј; Ϫ998, 5Ј-gggggatccTTACCAGTATCTCCTATGAAGGGC-3Ј; Ϫ521, 5Ј-gggggatcc-CCAGTCTGTCCCGACGTGACTTCC-3Ј; Ϫ327, 5Ј-gggggatccGCGCTC-GGGCAAAGACTGCGAAG-3Ј; Ϫ170, 5Ј-gggggatccCTCATTTCCGTGG-GTAAAAAACCC-3Ј; Ϫ88, 5Ј-gggggatccGGTACGAAAAGGCGG-3Ј; Ϫ46, 5Ј-gggggatccGCTTGGTTTTCAGTC-3Ј. The sequence of all PCRderived constructs was confirmed by fluorescent automatic sequencing (Centro de Biología Molecular, DNA facility, Madrid, Spain).
The ⌬CAM-AI plasmid encoded a deletion mutant of a murine calcineurin catalytic subunit (27) . The IL-2-LUC plasmid containing the region Ϫ326 to ϩ45 of the human IL-2 promoter (30), the full-length human NFATc (p1SH107c), and the dominant negative NFATc (pSH102C⌬418) expression plasmids (31) were generously provided by G. Crabtree. The pCMV-TAM67 plasmid encoding a dominant negative mutant variant of c-Jun (32) was a gift of C. M. Zacharchuck.
mRNA Analysis-Total RNA was prepared from Jurkat T cells by the TRIzol reagent RNA protocol (Life Technologies, Inc.). Total RNA (1 g) was reverse transcribed into cDNA and used for PCR amplification with either human COX-2, or glyceraldehide-3-phosphate dehydrogenase specific primers by the RNA PCR core kit (Perkin-Elmer) as described previously (15) . Briefly, the PCR reaction was amplified by 20 -35 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1 min. Amplified cDNAs were separated by agarose gel electrophoresis and bands visualized by ethidium bromide staining. The data shown correspond to a number of cycles where the amount of amplified product is proportional to the abundance of starting material.
Transfection and Luciferase Assays-Transcriptional activity was measured using luciferase reporter gene assays in transiently transfected Jurkat cells or PBTs. Jurkat cells were transfected by Lipofectin reagent as recommended by the manufacturer (Life Technologies, Inc.). Briefly, exponential growing cells (1.5 ϫ 10 6 ) were incubated for 8 h at 37°C with a mixture of 1.5 g/ml of the correspondent reporter plasmid and 3 g/ml Lipofectin in 1 ml of Opti-MEM. In cotransfection experiments, 0.15-1.5 g/ml of the correspondent expression plasmid was included. The total amount of DNA in each transfection was kept constant by using the corresponding empty expression vectors. Cells were then resuspended in complete medium and incubated at 37°C an for additional 16 h. PBT transfection was performed by electroporation at 320 V and 1500 microfarads with a Bio-Rad Gene Pulser II (Bio-Rad). For electroporation, cells were resuspended at 1 ϫ 10 7 cells/0.5 ml in complete medium with 10 g of plasmid DNA. After electroporation cells were cultured in fresh medium at 37°C for 16 h. Transfected cells were exposed to different stimuli as indicated. Then, cells were harvested and lysed. Luciferase activity was determined by using a luciferase assay kit (Promega) with a luminometer Monolight 2010 (Analytical Luminescence Laboratory, San Diego, CA). Transfection experiments were performed either in duplicate or triplicate. The data presented are expressed as the mean of the determinations in relative luciferase units (RLUs) Ϯ S.D. A representative experiment from the several performed is shown in all cases.
Site-directed Mutagenesis-In vitro-directed mutagenesis was performed by the QuickChange site-directed mutagenesis kit (Stratagene). Synthetic oligonucleotide primers containing the desired mutation and complementary to opposite strands of the corresponding COX-2 promoter constructs were extended by using Pfu turbo DNA polymerase, generating a mutated plasmid: COX-2 dNFAT mutant primer 5Ј-GGGGAGAGGAGttAAcAATTTGTGGGGGGTACG-3Ј, COX-2 pNFAT mutant primer 5Ј-GGGGTACGAAAAGGCGtctAGAAACAGctgTTTCGTC-ACATGGG -3Ј, and COX-2 CRE mutant primer 5Ј-GAAACAGTCATTTgagCtCATGGGCTTGGTTTTCAG -3Ј. The oligonucleotide 5Ј-GAAACAGctgTTTgagCtCATGGGCTTGGTTTTCAG-3Ј was used to generate the double mutant P2-192 pNFAT and CRE-MUT by using the construct P2-192 pNFAT MUT as the template. Lowercase letters in the sequence of the primers indicate mutated positions. Mutagenesis of more than one site was done by subsequent mutation of the corresponding previously mutated construct. The nucleotide sequence of the mutants was confirmed by automatic DNA sequencing.
Electrophoretic Mobility Shift Assays-Nuclear extracts from Jurkat cells unstimulated or stimulated with 15 ng/ml PMA plus 1 M Ion were prepared as described previously (33) . Cells were resuspended in 400 l of ice-cold buffer A (10 mM HEPES, pH 7.6, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.75 mM Spermidine, 0.15 mM Spermine, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 10 mM Na 2 MoO 4 , 1 g/ml pepstatin, and leupeptin and aprotinin at 2 g/ml each). After 15 min on ice, cells were lysed with 0.6% (v/v) Nonidet P-40. The nuclear pellet was extracted with 50 l of buffer C (20 mM HEPES, pH 7.6, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 10 mM Na 2 MoO 4 , 1 g/ml pepstatin, and leupeptin and aprotinin at 4 g/ml each). Nuclear extracts were collected and stored at Ϫ80°C. Protein concentration was determined by the Bradford assay (Bio-Rad).
Gel retardation assays were performed as in Martínez-Martínez et al. (33) . Nuclear extracts (3-5 g) were incubated with 1 mg/ml of poly(dIdC) in DNA binding buffer (2% (w/v) polivinyl ethanol, 2.5% (v/v) glycerol, 10 mM Tris, pH 8, 0.5 mM EDTA, 0.5 mM dithiothreitol on ice for 10 min. Then, 100,000 cpm of 32 P-labeled double-stranded oligonucleotides was added and incubated at room temperature for 40 min. In competition experiments, a 20-fold molar excess of unlabeled oligonucleotides was added to the binding reaction mixture prior to the probe. Supershift assays were performed by incubating nuclear extracts with either preimmune serum or anti-all NFATs antisera prior to the addition of the probe. Anti-all NFATs 674 rabbit antiserum was raised against the synthetic peptide NH 2 -SDIELRKGETDIGRKNTRC coupled to carrier protein hemocyanin as described by Liu et al. (34) . This peptide has been previously used to generate the anti-all NFATs 796 antiserum that efficiently recognized NFAT-1, -2, -3, and -4 members (35) . DNA⅐protein complexes were resolved by polyacrylamide gel electrophoresis on a 4% nondenaturing gel. The sequences of the oligonucleotides (5Ј to 3Ј) used were: gatcGGAGGAAAAACTGTTTCATACAG-AAGGCGT (distal NFAT site of the human IL-2 promoter), CGCTTG-ATGAGTCAGCCGGGAA (AP-1 consensus oligonucleotide), ATTCGA-TCGGGGCGGGGCGAGC (SP-1 consensus oligonucleotide), tcgaCAA-GGGGAGAGGAGGGAAAAATTTGTGGC (nucleotides Ϫ117 to Ϫ91 containing the putative NFAT distal site of the COX-2 promoter), tcgaCAAAAGGCGGAAAGAAACAGTCATTTC (nucleotides Ϫ82 to Ϫ58 including the putative NFAT/AP-1 proximal site of the COX-2 promoter).
RESULTS

Analysis of COX-2 Promoter Activity in T Cells-
We have previously shown that COX-2 gene expression is induced in T cells by stimuli resembling T cell activation such as TCR crosslinking or phorbol ester plus calcium ionophore treatment (15, 36) . To further explore the transcriptional regulation of this gene, we studied the COX-2 promoter-driven transcription in transiently transfected Jurkat T cells and human PBTs. For this purpose we cloned a region spanning from Ϫ1796 to ϩ104 bp relative to the transcription start site of the human COX-2 gene in the reporter plasmid pXP2 (P2-1900). As shown in Fig.  1A , luciferase activity of this construct was strongly up-regulated upon activation by PMA plus Ion, a treatment that mimics T cell activation. To map the regions responsible for this induction, subsequent 5Ј-deletions ranging from Ϫ998 down to Ϫ170 bp were generated. Although absolute values for basal activity of these constructs slightly varied, inducibility for all of them were similar. It was also noticeable that basal activity of a construct spanning Ϫ898 bp from the transcription start site of the COX-1 promoter (P1-1009) was not induced upon PMA plus Ion treatment (Fig. 1A) .
Combined treatment with PMA plus Ion was required to get the maximal induction (8 -12-fold) of COX-2 promoter constructs in Jurkat T cells. PMA treatment alone led a 2-3-fold induction, whereas single treatment with calcium ionophore did not induce transcription from this promoter at all (Fig. 1B) . Moreover, no differences were observed again among the different COX-2 promoter constructs. Similar results were obtained when these COX-2 promoter constructs were transfected in purified human resting T lymphocytes isolated from peripheral blood. As shown in Fig. 1C , luciferase activity of transfected constructs P2-1906 and P2-274 was induced by PMA or PMA plus Ion in purified T lymphocytes thus confirming the data obtained in the Jurkat T cell line in a more physiological setting.
To compare the regulation of the promoter with the expression of the endogenous gene in T cells, RNA isolated from Jurkat cells was analyzed by reverse transcriptase-PCR. Whereas PMA treatment slightly induced COX-2 expression, maximal induction occurred after PMA plus Ion treatment.
However, treatment with Ion alone did not increase COX-2 expression (Fig. 1D) . These results demonstrated that regulation of COX-2 promoter activity paralleled transcriptional activation of the endogenous gene in T cells.
Involvement of the Ca 2ϩ /Calcineurin Pathway in the Transcriptional Activation of COX-2 Promoter-COX-2 mRNA induction was completely abolished by treatment with the immunosuppressive drug CsA in Jurkat T cells (Fig. 1D) . To determine whether this CsA-mediated inhibition occurred by interference with the transcriptional activity of the human COX-2 promoter, we transfected T cells with the P2-1906 and P2-274 promoter constructs and analyzed their activity upon activation in the presence of CsA. Treatment with CsA abrogated induced luciferase activity of the P2-1900 and P2-274 promoter constructs both in Jurkat cells and PBTs (Fig. 2, A  and B) .
The fact that COX-2 promoter activity was CsA-sensitive pointed to an involvement of the Ca 2ϩ /calmodulin phosphatase calcineurin, the major target of CsA, in the transcriptional induction of the COX-2 gene in T lymphocytes. Calcineurin is responsible for NFAT dephosphorylation and subsequently for the NFAT-dependent transactivation of genes (20 -23, 37) . To further confirm the role of calcineurin in the regulation of COX-2 expression, we cotransfected the P2-274 promoter construct along with an expression plasmid (⌬CAM-AI) encoding a deletion mutant of a murine constitutively active calcineurin catalytic subunit. ⌬CAM-AI has been previously described to efficiently substitute the calcium signal for activation of NFATdriven transcription. Cotransfection of ⌬CAM-AI is sufficient to fully activate the IL-4 promoter that can be maximally induced by a calcium signal alone (38) . Moreover, this mutant is able to act in synergy with PMA bypassing the calcium requirement for induction of NFAT-mediated transcription of the IL-2 promoter that requires costimulation of calcium and PKC-mediated signaling pathways for full activation (27) . Cotransfection of ⌬CAM-AI slightly induced P2-274 COX-2 promoter basal activity but strongly cooperated with PMA to activate the COX-2 promoter in a similar way as for the IL-2 promoter (Fig. 3) .
Requirement of NFAT and AP-1 Transcription Factors in the Activation of the COX-2 Promoter in T Cells-The above results
indicate that COX-2 promoter regulation was very similar to that described for the IL-2 promoter because of the inhibition by CsA and the induction by calcineurin. It has been shown that two functional NFAT sites in the IL-2 promoter are essential for the calcineurin-mediated regulation of the expression of this gene (19, 37, 39) . To tested whether NFAT might be important for the regulation of COX-2 promoter activity as well, we performed cotransfection experiments using an NFATc (NFAT2 and NFATc1) expression vector together with the P2-274 construct or the IL2-LUC reporter plasmid included as a control. In agreement with the proposed role of NFAT as a critical regulator of the IL-2 gene (31), overexpression of the NFAT protein efficiently transactivated the IL-2 promoter. Interestingly, COX-2 promoter activity was similarly enhanced by NFATc cotransfection (Fig. 4A) . Moreover, cotransfection of Jurkat T cells with a dominant negative version of NFATc previously described to abolish IL-2 promoter activity (31) resulted in more than 90% inhibition of the induced activity of both the COX-2 and the IL-2 promoter (Fig. 4A) , supporting the hypothesis that NFAT was required in the regulation of COX-2 gene expression in T cells.
Because NFAT-dependent transcriptional activation of several promoters such as IL-2 requires the cooperation with AP-1 to efficiently drive transcription (37, 40) , we next examined the role of AP-1 in the regulation of COX-2 promoter activity. For this purpose we used a dominant negative mutant version of c-Jun named TAM67 that lacks the transactivation domain. In agreement with previous work (32), co-expression of TAM67 in T cells markedly inhibited the induction of IL-2 promoter by PMA plus Ion (Fig. 4B) . Similarly, cotransfection of the c-Jun dominant negative isoform in Jurkat cells along with the P2-274 reporter plasmid resulted in a clear suppression of COX-2 promoter inducibility by PMA plus Ion (Fig. 4B) . These data supported the hypothesis that AP-1 transcription factors played an important role in PMA plus Ion-mediated transcriptional induction of the human COX-2 gene in T cells.
Identification of Functional NFAT Sites within the COX-2 Promoter-To localize the minimal regions involved in the inducibility by PMA plus Ion of the COX-2 promoter, further 5Ј-deletions were created from the P2-274 construct (Fig. 5A) . Deletion of a region of 83 bp generated the P2-192 construct, which displayed a reduced ability to be induced by PMA plus Ion both in Jurkat cells and PBTs. This induction was still abrogated with CsA treatment. However, a shorter construct (P2-150) could not be induced at all (Fig. 5, B and C) . Thus, the regions between Ϫ170 to Ϫ88 and Ϫ88 to Ϫ46 might include sequences important for the CsA-sensitive induction of COX-2 promoter in T cells by PMA plus Ion. Sequence analysis of these regions revealed the presence of two putative NFAT cis-acting elements named COX-2 NFAT distal (COX-2 dNFAT) and COX-2 NFAT proximal (COX-2 pNFAT) elements. Both sequences contained the minimal GGAAA NFAT core consensus sequence. In addition, the COX-2 pNFAT element contained an adjacent AP-1-like site. Noteworthy, both regions were extremely conserved among human, rat, and mouse genomic sequences not only in nucleotide composition but also in their relative localization from the transcription start site (Fig. 6) .
To analyze the functionality of these sequences as NFAT binding elements, we performed electrophoretic mobility shift assays with nuclear extracts of Jurkat T cells using DNA probes of this sites and of the distal NFAT site in the IL-2 gene for comparison. As expected, a retarded complex was resolved in nuclear extracts from Jurkat stimulated by PMA plus Ion with the IL-2 NFAT probe. This band was efficiently competed with a 20-fold molar excess of unlabeled IL-2 NFAT an AP-1 consensus oligonucleotides and also by both COX-2 NFAT proximal and distal oligonucleotides but not by an heterologous SP-1 consensus oligonucleotide (Fig. 7A) . Moreover, both distal and proximal NFAT sequences of the COX-2 promoter bound proteins of nuclear extracts from PMA plus Ion-stimulated Jurkat cells. Efficient competition with cold COX-2 NFAT oligonucleotides and not with an unrelated sequence as the SP-1 consensus motif indicated the specificity of the complexes (Fig. 7, B and C) . In addition, binding to the COX-2 NFAT probes was efficiently competed with an excess of cold oligonucleotides corresponding to the proximal NFAT site of the IL-2 promoter and, in the case of the COX-2 pNFAT site, by a consensus AP-1 response element oligonucleotide (Fig. 7C) . However, AP-1 consensus oligonucleotides did not compete for the binding to the distal site, indicating the absence of proteins of the Jun and Fos family in this retarded band (Fig. 7B) . Furthermore, these inducible complexes were severely diminished when nuclear extracts from cells stimulated in the presence of CsA were used (Fig. 7, B and C, lane 7) .
To unambiguously determine the presence of NFAT proteins in the retarded complex, we performed electrophoretic mobility shift assays with nuclear extracts from Jurkat cells and COX-2 NFAT probes in the presence of polyclonal antisera specific for NFAT-1, -2, -3, and -4 isoforms directed against a common epitope located in the DNA binding domain. As shown in Fig. 8 , whereas the preimmune serum did not alter substantially the retarded complexes in samples with nuclear extracts of PMA plus Ion-treated cells, incubation with either the anti-all NFATs 796 or 674 antisera efficiently prevented the binding. These results demonstrate the binding of NFAT proteins to the COX-2 NFAT distal and proximal sites in response to PMA plus Ion treatment of T cells.
To investigate the role that both COX-2 NFAT sites played in COX-2 induction, mutations were introduced into each of these sites (Fig. 9 ). Transient transfections with the P2-274 promoter construct containing either COX-2 dNFAT or pNFAT sites mutated showed around 40 -50% loss in the inducibility by PMA plus Ion, whereas mutation of both sites resulted in more than 80% reduction (Fig. 9) . These results were consistent with the observed inducible response of the P2-192 construct, which lacks the entire dNFAT site (around 40% of P2-274). Consistently, mutation of the remaining pNFAT site in P2-192 further decreased the inducibility by PMA plus Ion to the levels observed with the P2-274 double mutant. These results clearly indicated that both COX-2 distal and proximal NFAT sites significantly contributed to the activation of the human COX-2 promoter in T cells. To determine the possible contribution of the CRE element to the induction of the COX-2 promoter, CRE mutant constructions were generated. As shown in Fig. 9 , mutation of this site did not significantly alter the induction of COX-2 promoter by PMA ϩ Ion in T cells. DISCUSSION Recently, we have demonstrated that COX-2 is transcriptionally up-regulated in T cells and that it behaves as an early inducible gene involved in the T cell activation process. Moreover, blockade of COX-2 enzymatic activity by nonsteroidal anti-inflammatory drugs down-regulates T cell activation (15, 36) . In the present work we have extended our observations by analyzing the regulation of the activity of the COX-2 promoter in T cells. Our results clearly show that COX-2 promoter activity was markedly induced after T cell activation. Conversely, COX-1 promoter-driven luciferase activity was not augmented FIG. 6 . Comparison of the ؊117/؊87 and ؊82/؊58 nucleotide sequences of the human COX-2 5-flanking region with those of rat and mouse genes. Uppercase letters indicate identical bases between human and rat or mouse sequences, whereas lowercase letters show aligned nonidentical bases. The boxed areas show comparison between NFAT and AP-1 consensus sequences and those corresponding for distal (COX-2 dNFAT) and proximal (COX-2 pNFAT) NFAT sites in the 5Ј-flanking sequence of the human COX-2 gene.
FIG. 7.
Electrophoretic mobility shift assays of the COX-2 dNFAT and pNFAT probes. Nuclear extracts from Jurkat cells stimulated with PMA ϩ Ion or pretreated with CsA were analyzed by electrophoretic mobility shift assay. The specific PMA ϩ Ion-induced complexes are indicated by arrows. Gel shift assays were performed using oligonucleotides corresponding to: (A) the distal NFAT site of the IL-2 promoter, (B) the human COX-2 distal NFAT site (nucleotides Ϫ117 to Ϫ91), and (C) the human COX-2 proximal NFAT site (nucleotides Ϫ82 to Ϫ58). A 20-fold molar excess of unlabeled IL-2 NFAT, COX-2 dNFAT, COX-2 pNFAT, SP-1, and AP-1 consensus oligonucleotides was added to the binding reaction mixtures to determine the specific binding. upon activation. It is known that the pattern of expression of these isoforms in mammalian tissues is different. Whereas COX-1 is constitutively expressed in almost all tissues, COX-2 is rapidly induced by serum, phorbol esters, mitogens, and cytokines in many cell types including synoviocytes, endothelial cells, fibroblasts, and monocyte/macrophages (reviewed in Refs. 1-3 ). The analysis of the 5Ј-flanking regions of these genes reveals little similarity, which likely contributes to their differential pattern of expression (4 -9, 41). COX-1 has a TATAless promoter that does not display any significant inducible transcription. On the other hand, the promoter region of the COX-2 gene contains a TATA box and binding sites for transcription factors including nuclear factor-B (12, 14) , nuclear factor IL-6/CCAAT-enhancer binding protein (5, 42, 43) and cyclic AMP-response element-binding proteins (10, 11) . In addition to these sites, in this work we have identified two NFAT binding sites that are essential for the induction of COX-2 expression in T cells.
Maximal induction of COX-2 promoter activity in T cells occurred with stimuli mimicking T cell activation through the TCR⅐CD3 complex such as the simultaneous treatment with the phorbol ester PMA plus the calcium ionophore A23187. However, the contribution of these agents to COX-2 up-regulation is different; whereas PMA treatment was able to promote COX-2 gene transcriptional activation up to 4-fold, single treatment with Ion was not sufficient to induce COX-2 gene expression either measured by the activity of its promoter or by analyzing COX-2 mRNA levels. These results pointed to a synergistic cooperation of both PKC and Ca 2ϩ pathways for full activation. Similar requirements have been reported for the activation of many important T cell activation genes including IL-2 (4, 5, 22, 46) . It has been shown that PMA rapidly induces COX-2 mRNA in human epithelial cells, endothelial cells, and monocytes (44 -46) and also in murine fibroblasts (47, 48) . In addition, activation of components of the AP-1 transcription factor complex such as Fos/Jun proteins by PMA has been reported to be important for the activation of the transcription of the COX-2 gene in non-T cells (46, 49, 50) . Both AP-1 activity and COX-2 mRNA expression are induced in T cells by engagement of the TCR⅐CD3 complex with antigens or specific antibodies as well as by phorbol esters or mitogens (51-53), which is consistent with the potential role of AP-1 in the induction of COX-2 promoter in T cells. In support of this was the fact that a c-Jun dominant negative mutant efficiently abrogated this induction. Besides, the efficient competition of AP-1 oligonucleotides for the binding of NFAT to the proximal NFAT site of this promoter pointed to an important role of AP-1 components in the induction of the COX-2 promoter by the interaction with NFAT. Although regulation of COX-2 promoter activity by AP-1 transcription factor has been reported to occur through a CRE element in the COX-2 promoter in NIH 3T3 cells (50) , our results discard the involvement of this element in the induction of the COX-2 promoter in T cells.
We have shown that COX-2 mRNA induction was abrogated by treatment with the immunosuppressive drug cyclosporin A. Even more, co-expression of a constitutively active calcineurin catalytic subunit cooperated synergistically with PMA in COX-2 promoter induction, therefore confirming the involvement of the Ca 2ϩ /calcineurin pathway in the regulation of this gene in T cells. As reported for the IL-2 promoter and NFATdependent reporter constructs, the presence of this mutant bypasses the requirements of Ca 2ϩ (27, 38) . CsA was able to inhibit both endogenous Ca 2ϩ /calcineurin activation and PMA/ ⌬CAM-AI-mediated transcription confirming that the calcineurin signaling pathway is the CsA-sensitive component in TCR signal transduction required for COX-2 induction in T lymphocytes. Activation of calcineurin results in dephosphorylation and activation of NFAT proteins (19, 37) , which enter the nucleus where they bind to NFAT-responsive elements in the 5Ј-flanking sequence of several genes such as IL-2, IL-4, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor ␣ among others (37) . As a consequence, transcriptional activation of these genes occurs. In agreement with that pathway, we have shown here that overexpression of the NFATc (NFAT2 and NFATc1) isoform in T cells enhanced PMA and PMA plus Ion COX-2 promoter activity in a similar fashion as in the case of the IL-2 promoter. On the other hand, expression of a dominant negative NFAT version abolished PMA plus Ion-induced transcription, thus evidencing the involvement of NFAT transcription factor in the induction of the COX-2 promoter. Moreover, we have identified two NFAT binding sites located in a highly conserved region both in sequence composition as well as in relative position to the transcription start site among rat, mouse, and human genes, suggesting common mechanisms of transcriptional regulation of COX-2 gene in T cells among mammalian species. Furthermore, our results may provide an explanation of previous data describing a CsAsensitive induction of COX-2 mRNA by IL-1 or tumor necrosis factor in rat mesangial cells (54) . The COX-2 NFAT distal site appears to be a pure NFAT site, evidenced for the absence of any surrounding predicted AP-1 binding sequences and for the lack of competition of an AP-1 consensus oligonucleotide for the protein binding to this sequence. On the other hand, the COX-2 NFAT proximal site contains a highly homologous AP-1 site adjacent to the NFAT core GGAAA motif. Both NFAT sites lie within the first 170 bp upstream of the transcription initiation site, which contains most of the sites previously described to be important for induced transcription of COX-2 in non-T cells such as the TATA box, an E-box (13), a nuclear factor IL-6/ CCAAT-enhancer binding protein motif (5, 42, 43) , and a cyclic AMP-response element (10, 11) . However, the importance of these cis-acting acting elements in COX-2 transcriptional induction depends on the cell type and the stimuli used (5, 10, 11, 14, 42, 46) . In this context, it is noteworthy that the previously described nuclear factor-B-dependent elements of the COX-2 promoter were absent in this region. Our results assign a predominant role to the NFAT and AP-1 sites for COX-2 pro- moter regulation in human T cells. Thus, selective mutation of these sites diminished more than 80% the inducibility of the promoter in these cells. Both distal and proximal NFAT sites seemed to be required for full transcriptional activation of the human COX-2 gene. The presence of multiple NFAT sites is a common feature of NFAT-dependent promoters as shown for the IL-2, IL-4, granulocyte-macrophage colony stimulating factor, and tumor necrosis factor ␣ promoters (reviewed in Ref. 37 ).
In conclusion, our results implicate the CsA-sensitive Ca 2ϩ / calcineurin/NFAT and PKC/AP-1 pathways in the regulation of COX-2 gene expression in T lymphocytes in a similar manner to that reported for other NFAT-dependent genes important in the T cell activation process such as IL-2. Growing evidence supports the role of COX-2, eicosanoids, and nonsteroidal antiinflammatory drugs in the homeostasis of the immune system, regulating both humoral and cell-mediated immunity and modulating cytokine production as well as T cell proliferation and activation (15, (55) (56) (57) (58) (59) (60) . Moreover, COX-2 inhibitors have been proven to be useful in T-cell-mediated inflammatory diseases such as rheumatoid arthritis (61, 62) . In addition, cyclosporin A has been demonstrated to have beneficial symptomatic effects in inflammatory diseases like psoriasis and rheumatoid arthritis (63) . Our data identify COX-2 as a new target for the immunosuppressive and anti-inflammatory actions of CsA in T-cell-mediated inflammatory diseases like psoriasis and rheumatoid arthritis. Data presented here may provide an explanation of the effectiveness of CsA treatment in rheumatoid arthritis through the inhibition of COX-2 induction in addition to the known immunosuppressive effects of the drug. FIG. 9 . Mutational analysis of the NFAT sites in the COX-2 promoter region. A, sequences of the oligonucleotides used for site-directed mutagenesis of the NFAT distal (COX-2 dNFAT-MUT) and proximal (COX-2 pNFAT-MUT) sites corresponding to regions Ϫ115 to Ϫ83 or Ϫ90 to Ϫ47 of the human COX-2 promoter. Bases mutated in the NFAT-MUT oligonucleotides are indicated by lowercase letters. B, Jurkat T cells were transiently transfected with COX-2 promoter constructs P2-274, P2-192, and same constructs containing dNFAT, pNFAT, and/or CRE sites mutated. Cells were cultured in the absence or presence of PMA ϩ Ion and then assayed for luciferase activity. Assays were performed in triplicate and results are shown as RLUs Ϯ S.D.
